These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 38810600)

  • 1. Eculizumab in Adolescent Patients With Refractory Generalized Myasthenia Gravis: A Phase 3, Open-Label, Multicenter Study.
    Brandsema JF; Ginsberg M; Hoshino H; Mimaki M; Nagata S; Rao VK; Ruzhansky K; Suresh N; Tiongson E; Yamanouchi H; Frick G; Hicks E; Liao S; Howard JF;
    Pediatr Neurol; 2024 Jul; 156():198-207. PubMed ID: 38810600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retrospective Analysis of Eculizumab in Patients with Acetylcholine Receptor Antibody-Negative Myasthenia Gravis: A Case Series.
    Datta S; Singh S; Govindarajan R
    J Neuromuscul Dis; 2020; 7(3):269-277. PubMed ID: 32444555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term efficacy of eculizumab in refractory generalized myasthenia gravis: responder analyses.
    Howard JF; Karam C; Yountz M; O'Brien FL; Mozaffar T;
    Ann Clin Transl Neurol; 2021 Jul; 8(7):1398-1407. PubMed ID: 34043280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Experience with Eculizumab in Treatment-Refractory Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis.
    Katyal N; Narula N; Govindarajan R
    J Neuromuscul Dis; 2021; 8(2):287-294. PubMed ID: 33325394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.
    Howard JF; Utsugisawa K; Benatar M; Murai H; Barohn RJ; Illa I; Jacob S; Vissing J; Burns TM; Kissel JT; Muppidi S; Nowak RJ; O'Brien F; Wang JJ; Mantegazza R;
    Lancet Neurol; 2017 Dec; 16(12):976-986. PubMed ID: 29066163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A real-life experience with eculizumab and efgartigimod in generalized myasthenia gravis patients.
    Pane C; Di Stefano V; Cuomo N; Sarnataro A; Vinciguerra C; Bevilacqua L; Brighina F; Rini N; Puorro G; Marsili A; Garibaldi M; Fionda L; Saccà F
    J Neurol; 2024 Sep; 271(9):6209-6219. PubMed ID: 39080054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eculizumab: A Review in Generalized Myasthenia Gravis.
    Dhillon S
    Drugs; 2018 Mar; 78(3):367-376. PubMed ID: 29435915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Consistent improvement with eculizumab across muscle groups in myasthenia gravis.
    Mantegazza R; O'Brien FL; Yountz M; Howard JF;
    Ann Clin Transl Neurol; 2020 Aug; 7(8):1327-1339. PubMed ID: 32700461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis.
    Vu T; Meisel A; Mantegazza R; Annane D; Katsuno M; Aguzzi R; Enayetallah A; Beasley KN; Rampal N; Howard JF
    NEJM Evid; 2022 May; 1(5):EVIDoa2100066. PubMed ID: 38319212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world experience with eculizumab and switching to ravulizumab for generalized myasthenia gravis.
    Tokuyasu D; Suzuki S; Uzawa A; Nagane Y; Masuda M; Konno S; Kubota T; Samukawa M; Sugimoto T; Ishizuchi K; Oyama M; Yasuda M; Akamine H; Onishi Y; Suzuki Y; Kawaguchi N; Minami N; Kimura T; Takahashi MP; Murai H; Utsugisawa K
    Ann Clin Transl Neurol; 2024 May; 11(5):1338-1346. PubMed ID: 38572524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 'Minimal symptom expression' in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab.
    Vissing J; Jacob S; Fujita KP; O'Brien F; Howard JF;
    J Neurol; 2020 Jul; 267(7):1991-2001. PubMed ID: 32189108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension.
    Mantegazza R; Wolfe GI; Muppidi S; Wiendl H; Fujita KP; O'Brien FL; Booth HDE; Howard JF;
    Neurology; 2021 Jan; 96(4):e610-e618. PubMed ID: 33229455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial.
    Howard JF; Nowak RJ; Wolfe GI; Freimer ML; Vu TH; Hinton JL; Benatar M; Duda PW; MacDougall JE; Farzaneh-Far R; Kaminski HJ; ; Barohn R; Dimachkie M; Pasnoor M; Farmakidis C; Liu T; Colgan S; Benatar MG; Bertorini T; Pillai R; Henegar R; Bromberg M; Gibson S; Janecki T; Freimer M; Elsheikh B; Matisak P; Genge A; Guidon A; David W; Habib AA; Mathew V; Mozaffar T; Hinton JL; Hewitt W; Barnett D; Sullivan P; Ho D; Howard JF; Traub RE; Chopra M; Kaminski HJ; Aly R; Bayat E; Abu-Rub M; Khan S; Lange D; Holzberg S; Khatri B; Lindman E; Olapo T; Sershon LM; Lisak RP; Bernitsas E; Jia K; Malik R; Lewis-Collins TD; Nicolle M; Nowak RJ; Sharma A; Roy B; Nye J; Pulley M; Berger A; Shabbir Y; Sachdev A; Patterson K; Siddiqi Z; Sivak M; Bratton J; Small G; Kohli A; Fetter M; Vu T; Lam L; Harvey B; Wolfe GI; Silvestri N; Patrick K; Zakalik K; Duda PW; MacDougall J; Farzaneh-Far R; Pontius A; Hoarty M
    JAMA Neurol; 2020 May; 77(5):582-592. PubMed ID: 32065623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis: A subgroup analysis of the REGAIN open-label extension study.
    Murai H; Uzawa A; Suzuki Y; Imai T; Shiraishi H; Suzuki H; Okumura M; O'Brien F; Wang JJ; Fujita KP; Utsugisawa K;
    J Neurol Sci; 2019 Dec; 407():116419. PubMed ID: 31698177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of eculizumab in ventilator-dependent myasthenia gravis patients.
    Usman U; Chrisman C; Houston D; Haws CC; Wang A; Muley S
    Muscle Nerve; 2021 Aug; 64(2):212-215. PubMed ID: 34008175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eculizumab in refractory generalized myasthenia gravis previously treated with rituximab: subgroup analysis of REGAIN and its extension study.
    Siddiqi ZA; Nowak RJ; Mozaffar T; O'Brien F; Yountz M; Patti F;
    Muscle Nerve; 2021 Dec; 64(6):662-669. PubMed ID: 34590717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. United States clinical practice experience with eculizumab in myasthenia gravis: symptoms, function, and immunosuppressant therapy use.
    Habib AA; Klink AJ; Muppidi S; Parthan A; Sader SC; Balanean A; Gajra A; Nowak RJ; Howard JF;
    J Neurol; 2024 Sep; 271(9):6114-6126. PubMed ID: 39052039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term safety and efficacy of eculizumab in generalized myasthenia gravis.
    Muppidi S; Utsugisawa K; Benatar M; Murai H; Barohn RJ; Illa I; Jacob S; Vissing J; Burns TM; Kissel JT; Nowak RJ; Andersen H; Casasnovas C; de Bleecker JL; Vu TH; Mantegazza R; O'Brien FL; Wang JJ; Fujita KP; Howard JF;
    Muscle Nerve; 2019 Jul; 60(1):14-24. PubMed ID: 30767274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eculizumab improves fatigue in refractory generalized myasthenia gravis.
    Andersen H; Mantegazza R; Wang JJ; O'Brien F; Patra K; Howard JF;
    Qual Life Res; 2019 Aug; 28(8):2247-2254. PubMed ID: 30905021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ravulizumab: A Review in Generalised Myasthenia Gravis.
    Kang C
    Drugs; 2023 Jun; 83(8):717-723. PubMed ID: 37166620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.